SSA
MRSN

Schonfeld Strategic Advisors’s Mersana Therapeutics MRSN Stock Holding History

Schonfeld Strategic Advisors’s Portfolio MRSN Stock Details MRSN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-2,000
Closed -$9.5K – 2100
2023
Q2 		$9.5K Buy
+2,000
New +$293K ﹤0.01% 1921

Other funds holding MRSN

NI
Nextech Invest Zurich, Switzerland $1.42B AUM 304.47% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
AV
Alamea Verwaltungs Edison, New Jersey $135M AUM 36.32% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $1.94B AUM 374.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Schonfeld Strategic Advisors's MRSN Position: Q4 2025 in Review

Schonfeld Strategic Advisors sold out of Mersana Therapeutics (MRSN) in Q4 2025, closing a stake of 273,579 shares — an estimated $2.12M sold.

Schonfeld Strategic Advisors first reported a position in MRSN in Q2 2017 and held it in 20 quarters. The position peaked at $5.98M in Q2 2024. 51 funds tracked by Wall St. Rank hold MRSN as of Q4 2025.

  • Schonfeld Strategic Advisors reported no remaining Mersana Therapeutics position as of Q4 2025 after selling out during the quarter.
  • Schonfeld Strategic Advisors sold 273,579 Mersana Therapeutics shares in Q4 2025, an estimated $2.12M.
  • Schonfeld Strategic Advisors first reported a position in Mersana Therapeutics in Q2 2017 and held it in 20 quarters.
  • Schonfeld Strategic Advisors's Mersana Therapeutics position peaked at $5.98M in Q2 2024.
  • 51 funds tracked by Wall St. Rank held Mersana Therapeutics as of Q4 2025.

Based on Schonfeld Strategic Advisors's 13F filing for Q4 2025, filed 17 Feb 2026.